* Ginkgo Bioworks Holdings Inc reported a quarterly adjusted loss of 94 cents per share for the quarter , higher than the same quarter last year, when the company reported EPS of $-6.40. The mean expectation of five analysts for the quarter was for a loss of $2.72 per share. Wall Street expected results to range from $-2.99 to $-2.40 per share.
* Revenue rose 60.6% to $89.05 million from a year ago; analysts expected $45.00 million.
* Ginkgo Bioworks Holdings Inc's reported EPS for the quarter was a loss of $1.08.
* The company reported a quarterly loss of $56.4 million.
* Ginkgo Bioworks Holdings Inc shares had risen by 2.9% this quarter and lost 87.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 2.9% in the last three months.
* In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 4 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "sell"
Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $8.00 This summary was machine generated from LSEG data November 13 at 02:20 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -2.72 -0.94 Beat
Jun. 30 2024 -3.12 -2.80 Beat
Mar. 31 2024 -3.33 -3.20 Beat
Dec. 31 2023 -3.87 -4.40 Missed
Comments